BriaCell Therapeutics

BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Our mission is to expand the range of effective immunotherapy options by pursuing a personalized approach to cancer treatment, ultimately offering hope to cancer patients and their families.

Our vision is to be a leader in advancing cancer treatment through personalized immunotherapy, delivering innovative solutions with the potential to dramatically improve patient outcomes.

In 2018, BriaCell was named a ‘Top 10 Biotech Company by Global Health and Pharma’. In 2019, BriaCell Therapeutics won the Startup World Cup in San Francisco, which is the world’s most prestigious startup competition and was one of the winners of the San Diego Venture Group ‘Excellence in Patient Care’ award.